Successful capital increase for BioAlliance Pharma

Over-subscribed transaction

€16.64 million raised

(Offering notice number 11-280 dated 30th June 2011 approved by the French financial market regulator AMF)

Paris, July 26, 2011 – BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to specialty and orphan oncology products, today announces its successful capital increase, with maintenance of preferential subscription rights launched on July 1st, 2011, for a total of €16,64 million raised.

"We are very pleased with the success of our capital increase achieved in a market environment turned out to be tough and unforeseeable, and we wish to thank our shareholders for their confidence and support to the Company's growth strategy", comments Judith Greciet, CEO of BioAlliance Pharma.

The raised funds will enable:

- To finance the development program of Livatag® in the treatment of primary liver cancer, with a phase III trial scheduled in 2012, in the wake of the significant survival data observed in the phase II trial.
- To complement the orphan products portfolio with targeted acquisitions, in addition to the 3 products already in clinical phase, in order to maximize market access opportunities while benefiting from the Company's know-how in the development and the registration of products.

« This financing will allow us to accelerate the development and market access of our most promising projects, as well as to enlarge our "oncology orphan products" portfolio, a key asset of our future growth", adds Judith Greciet.

Characteristics of the issuance

As the transaction was oversubscribed, all shares from the offer (3,395,943 new ordinary shares) will therefore be issued for a gross total amount of 16,640,120 Euros. The share capital will thus be increased from €3,395,943 to €4,244,928.75 divided into 16,979,715 shares of €0.25 nominal value per share.

The settlement and delivery of the new shares will occur on August 1, 2011 and 3,395,943 new shares will be listed on NYSE Euronext Paris on August 2, 2011 on the same listing line as the existing shares of the company (FR0010095596).

Partner of the transaction

BioAlliance Pharma thanks its advisory partners in this capital increase transaction, and especially:

Invest Securities : Advisor, Order centralizer

About BioAlliance Pharma

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products — BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products' commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.

BioAlliance Pharma has developed an advanced product portfolio:

Specialty products

Loramyc® /Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU US, Korea)

Sitavir® (Acyclovir Lauriad™) (labialis herpes): Positive phase III final results; registration status

Fentanyl Lauriad™ (chronic cancer pain): Positive preliminary Phase I results

Orphan Oncology products

Livatag® (Doxorubicin Transdrug™) in primary) liver cancer: Phase II results on survival

Clonidine Lauriad™ (mucositis): Phase II on going

AMEP® (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2010 Reference Document filed with the AMF on April 7, 2011, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).

BioAlliance Pharma SA
Judith Greciet, CEO
Tel +33 1 45 58 76 00
judith.greciet@bioalliancepharma.com
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com

ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com